An interventional study of Transcranial Direct Current Stimulation (tDCS) in Major Depression and Major Depression Disorders, sponsored by Medical University of South Carolina. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Depressive Disorder, Major by Medical University of South Carolina — 2 open to participants now, 4 under way, none of them phase 3. Depressive Disorder, Major · Medical University of South Carolina.
Among the 12 studies in Depressive Disorder, Major by Medical University of South Carolina, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 7 with no phase, and was the 11th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →2 of the 12 studies in Depressive Disorder, Major by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18–80
Medical University of South Carolina · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 1 · Phase 4 1
First in 2006; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 20 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 17 across the 11 interventional studies, 40 across the 1 observational. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Medical University of South Carolina is the lead sponsor of 875 studies on the registry; 165 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.
4 of the studies in Depressive Disorder, Major by Medical University of South Carolina that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07226011Medical University of South CarolinaAccelerated High-Dose tDCS for Depression | 2026-12-28 |
| NCT07369557Medical University of South CarolinaMindfulness Training During Accelerated TMS for Depression | 2026-12-30 |
| NCT06043401Medical University of South CarolinaTracking Brain Biomarkers and Renormalization Associated With Antidepressant Transcranial Magnetic Stimulation Therapy | 2027-04-01 |
| NCT05977439Medical University of South CarolinaRECOVERS - Realigning Emotion and COgnition Via prEcision Regulation networkS | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 12 studies in Depressive Disorder, Major by Medical University of South Carolina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, investigators are testing whether a higher dose of a non-invasive brain stimulation technique, called transcranial direct current stimulation (tDCS), can be safely used in people with depression. Participants will come to the Brain Stimulation Lab and receive mild electrical stimulation through electrodes placed on their scalp.
The study begins with a safety run-in, where the first few participants will receive stimulation at gradually increasing levels (2, 4, and 6 milliamps) while being closely monitored. If no serious side effects are found, later participants will receive repeated 6 milliamp sessions for 5 days total. Investigators will check skin comfort, mood, and overall tolerability after each session.
Major depressive disorder (MDD) remains one of the leading causes of disability worldwide, with many patients experiencing inadequate response to currently available treatments. Transcranial direct current stimulation (tDCS) has shown promise as a non-invasive, well-tolerated neuromodulation technique for depression, but nearly all prior studies have used lower current intensities (≤2 mA). Preliminary modeling and experimental work suggest that higher current dosing may be necessary to achieve sufficient engagement of cortical targets and produce stronger clinical effects.
The present study is designed to address this gap by systematically evaluating the safety, tolerability, and feasibility of high-dose tDCS delivered at 6 mA in adults with MDD. Establishing safety at this higher intensity is a critical step before pursuing larger efficacy trials. By carefully monitoring adverse events and skin integrity during an initial run-in phase, this study provides an evidence base for whether 6 mA tDCS can be safely implemented in a clinical population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this single-arm, open-label pilot study will receive high-dose transcranial direct current stimulation (tDCS) for major depressive disorder. Each participant undergoes twice-daily 20-minute sessions at 6 mA for five consecutive weekdays (total of 10 sessions). The first three participants complete an in-lab dose-escalation safety run-in (2 mA → 4 mA → 6 mA on Day 1) with a Day 2 skin integrity check before continuing at 6 mA twice daily for the remaining days. All participants complete baseline, post-intervention, and 4-week follow-up assessments of depressive symptoms, cognition, and tolerability.
Device: Transcranial Direct Current Stimulation (tDCS)
Participants receive transcranial direct current stimulation (tDCS) using a high-dose (6 mA) protocol delivered twice daily for five consecutive weekdays (10 sessions total). The first three participants complete a Day 1 in-lab dose-escalation (2 mA → 4 mA → 6 mA) with a Day 2 skin integrity check before continuing at 6 mA. All sessions last 20 minutes and are followed by adverse-event monitoring.
Number of Participants With Device-Related Serious Adverse Events
Defined as events requiring hospitalization or emergency care during the stimulation period.
Time frame: Up to 7 days
Number of Participants Completing All Scheduled Sessions Without Discontinuation
Up to 5 days
Time frame: Completion of all planned stimulation sessions without dropout due to adverse effects.
Mean Score on Adverse Event Questionnaire
Average Likert-scale ratings of discomfort, headache, or skin irritation.
Time frame: Daily during treatment (Days 1-5)
Change in Depression Severity Score From Baseline to Post-Treatment
Self-reported depression severity using a validated scale.
Time frame: Baseline to Day 5
Change in Cognitive Function Score From Baseline to Post-Treatment
Subjective cognitive performance measured via standardized instrument.
Time frame: Baseline to Day 5
Change in Mindfulness Score From Baseline to Post-Treatment
Self-reported mindfulness using a validated scale.
Time frame: Baseline to Day 5
Change in Depression Severity Score From Baseline to 4-Week Follow-Up
Longitudinal assessment of symptom durability.
Time frame: Baseline to 4 weeks post-treatment
Electric Field Intensity in Target Brain Regions Based on MRI Modeling
Retrospective modeling of intracerebral current flow using structural MRI.
Time frame: Within 30 days of MRI scan
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 12 months is below that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of South Carolina →